Risk Management is an approach to improving the quality and safety of health care by identifying circumstances that put patients and staff at risk and acting to prevent or control those risks.
This guidance provides evidence-based recommendations and good practice points for health professionals providing contraceptive services to women with cardiac disease in the UK.
A quality contraceptive service is vital in giving women and men of all ages choice and control over their reproduction, and is key to avoiding unplanned pregnancies and planning families. Contraception is a highly cost-effective intervention, which plays an important public health role in improving the lives of individuals, families and communities.
With the introduction of the process of revalidation for doctors, appraisal has been standardised and this has been supported by the Medical Appraisal Guide, Model Appraisal Form Guidance for this has already been published by the Royal College of Obstetricians and Gynaecologists and Faculty of Sexual and Reproductive Healthcare outlining what supporting evidence should be provided at appraisal.
Jaydess® is a levonorgestrel intrauterine system (LNG-IUS) newly launched in the UK for contraception. It is a smaller, lower dose version of the Mirena® LNG-IUS.
St Johns wort is a herbal product that is used for depressive symptoms and is known to have enzyme-inducing effects on cytochrome p450 enzymes. The MHRA statement highlights that in the last quarter of 2013, two ‘Yellow Card’ reports were received relating to unplanned pregnancies, in women with progestogen-only implants, suspected to be the result of an interaction with St John’s wort.
An article published in the British Medical Journal (BMJ) in November 2013, questioned whether women with HIV, or at high risk of contracting HIV, should use progestogen-containing contraceptives.
Various news stories have reported the findings detailed in the AAN press release which stated that compared to women who did not use hormonal contraceptives, women who did, were 35 percent more likely to develop Multiple Sclerosis and that the findings suggested that hormonal contraception may be contributing to the rise in the rate of MS among women.
This guidance provides evidence-based recommendations and good practice points for health professionals on the use of progestogen-only implants currently available in the UK. It is intended for any health care professional or health service providing contraception or conception advice in the UK.
Following a presentation at the annual meeting of the American Academy of Ophthalmology a number of media reports have reported a possible link between use of combined oral contraception (COC) and glaucoma. There is limited data investigating combined hormonal contraceptives on glaucoma. One cohort study suggested that 5 or more years of COC use was associated with a 25% increase in the risk of glaucoma. Two UK cohort studies did not find consistent evidence of an increased risk.